Abstract:Background: Colorectal cancer (CRC) is a heterogeneous disease; current research relies on cancer cell lines and animal cancer models, which may not precisely imitate inner human tumors and guide clinical medicine. The purpose of our study was to explore and further improve the process of producing three-dimensional (3D) organoid model and impel the development of personalized therapy. Methods: We subcutaneously injected surgically resected CRC tissues from a patient into BALB/c-nu mice to build patient-derived xenografts (PDXs). Isolated cells from PDXs at appropriate tumor size were mingled with Matrigel, and then seeded in ultra-low attachment 96-well plates at four cell densities (500, 1000, 2000, and 4000 single cells/well). Cells were cultured with advanced Dulbecco's Modified Eagle Medium/F12 medium additional with various factors added to maintain tumor's biological traits and growth activity. The growth curves of the four cell densities were measured after 24 h of culture until 25 days. We evaluated the effects of four chemotherapeutic agents on organoid model by the CellTiter-Glo® Luminescent Cell Viability Assay. Hematoxylin and eosin (H and E) staining of 3D organoids was performed and compared with patient and CRC PDX tissues. Furthermore, immunohistochemistry was performed, in which the organoids were stained with the proliferation marker, Ki-67. During the experimental process, a phase-contrast microscope was used. Results: Phenotype experimental results showed that 3D organoids were tightly packed together and grew robustly over time. All four densities of cells formed organoids while that composed of 2000 cells/well provided an adequate cultivation system and grew approximately 8-fold at the 25th day. The chemosensitivity of the four conventional drugs was [s]-10-hydroxycamptothecin > mitomycin C > adriamycin > paclitaxel, which can guide clinical treatment. Histological features of CRC patient's tumor tissues and mice tumor xenograft tissues were highly similar, with high-column-like epithelium and extracellular matrix. H and E-stained sections showed heterogeneous cell populations harbored in cancer organoids and were histologically similar to tumor tissues. The proliferation index was only 8.33% within spheroids, which exhibited confined proliferative cells that might be cancer stem cells. Conclusions: We successfully constructed a CRC organoid model that grew robustly over 25 days and demonstrated that 2000 cells/well in 96-well plate was a prime seeding density for cells to form organoids. The results confirmed that organoid model can be used for agent screening and personalized medicine.

Accuracy Of Using A Patient-Derived Tumor Organoid Culture Model To Predict The Response To Chemotherapy Regimens In Stage Iv Colorectal Cancer A Blinded Study

Patient-derived Organoid Model for Predicting the Chemoresponse in Patients With Colorectal Cancer

Patient-Derived Organoids (Pdo) As The Potential Model To Predict Treatment Outcome Of Rectal Cancer Patients Underwent Neo-Adjuvant Chemoradiotherapy

Patient-Derived Tumor Organoids Can Predict the Progression-Free Survival of Patients with Stage IV Colorectal Cancer after Surgery

Enhancing Prediction for Tumor Pathologic Response to Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Cancer by Dynamic Parameters from Clinical Assessments

Personalized Cancer Therapy Using a Patient-Derived Tumor Tissue Xenograft Model: a Translational Field Worthy of Exploring Further?

Establishment of a PDTT xenograft model of gastric carcinoma and its application in personalized therapeutic regimen selection.

IDDF2022-ABS-0105 Patient-derived Organoids Can Predict Chemotherapy Response of Gastric Cancers and Analysis of Its Molecular Characteristics

Patient-derived 3D Bioprinting Pan-Cancer Drug Screening Platform for Personalized Medicine.

Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients

Development of a Model to Predict Pathologic Response to Chemotherapy in Patients with Colorectal Liver Metastases

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

Genomic characteristics and drug screening among organoids derived fromnon-small celllung cancer patients

Organoid Culture of Isolated Cells from Patient-derived Tissues with Colorectal Cancer

Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer

Prediction of Clinical Precision Chemotherapy by Patient‐Derived 3D Bioprinting Models of Colorectal Cancer and Its Liver Metastases

Organoids from patient biopsy samples can predict the response of BC patients to neoadjuvant chemotherapy

Ovarian Cancer Patient-Derived Organoids Used as a Model for Replicating Genetic Characteristics and Testing Drug Responsiveness: A Preliminary Study

Rapid screening for individualized chemotherapy optimization of colorectal cancer: A novel conditional reprogramming technology-based functional diagnostic assay.

Patient-Derived Ex Vivo Cultures and Endpoint Assays with Surrogate Biomarkers in Functional Testing for Prediction of Therapeutic Response

Author Response for "use of Patient‐derived Tumor Organoid Platform to Predict the Benefit of Postoperative Adjuvant Chemotherapy for Poor Responders to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer"